We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients (EACH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00471965
Recruitment Status : Completed
First Posted : May 10, 2007
Last Update Posted : September 20, 2010
Information provided by:

Brief Summary:


  • Overall Survival (OS)


  • Time to Tumor Progression (TTP)
  • Response Rate (RR)
  • Improvement of Quality of Life (QoL)
  • Safety
  • Secondary resection rate

Condition or disease Intervention/treatment Phase
Carcinoma, Hepatocellular Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin Drug: Doxorubicin Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 371 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment
Study Start Date : March 2007
Primary Completion Date : March 2010
Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: A
Oxaliplatin + 5-Fluorouracil/Leucovorin
Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin

Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.

Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.

Repeated every 2 weeks

Active Comparator: B
Drug: Doxorubicin
Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.

Primary Outcome Measures :
  1. Overall survival [ Time Frame: From the date of randomization to the date of death due to any cause ]

Secondary Outcome Measures :
  1. Time to progression [ Time Frame: From the date of randomization to documentation of progression ]
  2. Response rate, secondary resection rate, quality of life [ Time Frame: From the date of randomization to the end of study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically, cytologically or clinically diagnosed (in patient with cirrhosis, Alpha-Fetoprotein(AFP)≥400μg/L and morphological evidence [contrast Computed Tomography(CT)/Magnetic Resonance Imaging(MRI)] of hypervascular liver tumor, elevated AFP level due to other reasons [germ cell carcinoma, progressive chronic hepatitis, pregnancy, etc] can be excluded) unresectable hepatocellular carcinoma, ineligible or if the patient does not consent to receive local invasive treatment (chemo-embolism, ablation, etc.).
  • At least one measurable lesion (on CT: ≥2cm, on spiral CT or MRI ≥1cm)
  • Have not received previous palliative systemic chemotherapy for metastatic disease. If the patient received previous systemic chemotherapy as adjuvant treatment, he must have been completed at least 12 months previously.
  • Patients progress after previous local treatment and at the time of randomization is at least 4 weeks after the last interventional therapy (Hepatic Artery Infusion, Trans-Artery Embolization or Trans-Artery Chemo-Embolization) or at least 8 weeks after the last radiotherapy/ablation/ Percutaneous Ethanol Injection to the target lesion.
  • Karnofsky Performance Score≥70, Barcelona of Cancer Liver Category stage B/C
  • Patients must have adequate organ and marrow function:

    • Neutrophilus≥1.5X10^9/L
    • Platelets≥75X10^9/L
    • Asparagine AminoTransferase,Alanine AminoTransferase<2.5 Upper Normal Limit(UNL)
    • Total Bilirubin<1.5 UNL
    • International Normalized Ratio<1.5
    • Child stage A or B
    • Normal base line Left Ventricular Ejection Fraction (LVEF result must be above or equal to the lower limit of normal for the institution)

Exclusion Criteria:

  • Documented allergy to platinum compound or to other study drugs.
  • Any previous oxaliplatin or doxorubicin treatment, except adjuvant treatment more than 12 months before the randomization.
  • Previous liver transplantation.
  • Patients concomitantly receiving any other anti-cancer therapy, including interferon-α and herbal medicine which was approved by local authority to be used as "anti-cancer" medicine, except radiotherapy to non-target lesion (bone metastasis, etc)
  • Patients who are receiving any other study treatments.
  • Pregnant or lactating women or women of childbearing potential without proper contraceptive methods.
  • History of other malignant diseases, except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.
  • Central nervous system metastasis
  • Other serious illness or medical conditions

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00471965

Sanofi-Aventis Administrative Office
Shanghai, China
Korea, Republic of
Sanofi-Aventis Administrative Office
Seoul, Korea, Republic of
Sanofi-Aventis Administrative Office
Taipei, Taiwan
Sanofi-Aventis Administrative Office
Bangkok, Thailand
Sponsors and Collaborators
Study Director: Benedict Blayney Sanofi

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Medical Affairs Study Director, Sanofi-aventis
ClinicalTrials.gov Identifier: NCT00471965     History of Changes
Other Study ID Numbers: OXALI_L_00858
First Posted: May 10, 2007    Key Record Dates
Last Update Posted: September 20, 2010
Last Verified: September 2010

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Liposomal doxorubicin
Antineoplastic Agents
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs